Relative Sensitivity to Change of the Erythrocyte Sedimentation Rate and Serum C-Reactive Protein Concentration in Rheumatoid Arthritis

Journal of Rheumatology

Volumn 31, Issue 5, 2004, Pages 884-895

  Ward, Michael M ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

C reactive protein; Erythrocyte sedimentation rate; Rheumatoid arthritis; Sensitivity to change

Indexed keywords

AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; AZATHIOPRINE; C REACTIVE PROTEIN; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; PENICILLAMINE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ARTICLE; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CLINICAL TRIALS; DATABASES, BIBLIOGRAPHIC; HUMANS; PREDICTIVE VALUE OF TESTS; RHEUMATOLOGY;

EID: 2342446543     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Donald F, Ward MM. Evaluative laboratory testing practices of United States rheumatologists. Arthritis Rheum 1998;41:725-9.
2. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
3. van Riel PLCM. Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis. Br J Rheumatol 1992;31:793-6.
4. Boers M, Tugwell P, Felson DT, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994;21 Suppl 41:86-9.
5. Streiner DL, Norman GR. Health measurement scales. A practical guide to their development and use. 2nd ed. New York: Oxford University Press; 1995.
6. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27 Suppl 3:S178-89.
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88.
8. Normand SLT. Meta-analysis; formulating, evaluating, combining, and reporting. Statist Med 1999;18:321-59.
9. Boerbooms AMT, Jeurissen MEC, Westgeest AAA, Theunisse H, van de Putte LBA. Methotrexate in refractory rheumatoid arthritis. Clin Rheumatol 1988;7:249-56.
10. Drosos AA, Psychos D, Andronopoulos AP, Stefanski-Nikou S, Tsianos EB, Moutsopoulos HM. Methotrexate therapy in rheumatoid arthritis. A two-year prospective follow-up. Clin Rheumatol 1990;9:333-41.
11. Jeurissen MEC, Boerbooms AMT, van de Putte LBA, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. Arthritis Rheum 1991;34:961-72.
12. Wiktorowicz KE, Lacki JK, Blazczak P, Cofta J, Mackiewicz SH. Does C-reactive protein modulate T-lymphocyte function in methotrexate-treated rheumatoid arthritis patients? J Invest Allergol Clin Immunol 1992;2:329-32.
13. Lacki JK, Schochat T, Sobieska M, et al. Immunological studies in patients with rheumatoid arthritis treated with methotexate or cyclophosphamide. Z Rheumatol 1994;53:76-82.
14. Wascher TC, Hermann J, Brezinschek R, et al. Serum levels of interleukin-6 and tumour-necrosis-factor-alpha are not correlated to disease activity in patients with rheumatoid arthritis after treatment with low-dose methotrexate. Eur J Clin Invest 1994;24:73-5.
15. Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 1997;36:345-52.
16. El Miedany YM, Abubakr AIH, El Baddini M. Effect of low dose methotrexate on markers of bone metabolism in patients with rheumatoid arthritis. J Rheumatol 1998;25:2083-7.
17. Rau R, Schleusser B, Herborn G, Karger T. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. J Rheumatol 1998;25:1485-92.
18. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
19. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65.
20. Ribbens C, Andre B, Jaspar J-M, et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 2000;27:888-93.
21. Lerndal T, Svensson B. A clinical study of CPH82 vs methotrexate in early rheumatoid arthritis. Rheumatology 2000;39:316-20.
22. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
23. Hamilton J, McInnes IB, Thomson EA, et al. Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann Rheum Dis 2001;60:566-72.
24. Ahern MJ, Bradley J, Harrison W, Laing B, Hollingsworth P, Bayliss C. A randomized double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Aust NZ J Med 1991;21:844-9.
25. van Rijthoven AWAM, Dijkmans BAC, Goei The HS, et al. Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double-blind, multicenter study. J Rheumatol 1991;18:815-20.
26. Lacki JK, Porawska W, Sobieska M, Mackiewicz SH, Muller W. Acute phase response in rheumatoid arthritis patients treated with low doses of cyclosporin A. Rheumatol Int 1994;14:39-40.
27. Landewe RBM, Goei The HS, van Rijthoven AWAM, Breedveld FC, Dijkmans BAC. A randomized, double-blind, 24-week controlled study of low-dose cyctosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994;37:637-43.
28. Ferraccioli G, Casatta L, Bartoli E. Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy. J Rheumatol 1996;23:1539-42.
29. Salaffi F, Carotti M, Cervini C. Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis. Scand J Rheumatol 1996;25:16-23.
30. Bendix G, Bjelle A. Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1996;35:1142-9.
31. Kim W-U, Cho M-L, Kim S-I, et al. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol 2000;27:324-31.
32. Kim W-U, Seo Y-I, Park S-H, et al. Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:514-7.
33. Neumann VC, Grindulis KA, Hubball S, McConkey B, Wright V. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. BMJ 1983;287:1099-102.
34. Nuver-Zwart IH, van Riel PLCM, van de Putte LBA, Gribnau FWJ. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis 1989;48:389-95.
35. Situnayake RD, McConkey B. Clinical and laboratory effects of prolonged therapy with sulfasalazine, gold or penicillamine: the effects of disease duration on treatment response. J Rheumatol 1990;17:1268-73.
36. Danis VA, Franic GM, Rathjen DA, Laurent RM, Brooks PM. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double-blind trial with sulphasalazine. Ann Rheum Dis 1992;51:946-50.
37. Peltomaa R, Palmela L, Helve T, Leirisalo-Repo M. Comparison of intramuscular gold and sulphasalazine in the treatment of early rheumatoid arthritis. A one year prospective study. Scand J Rheumatol 1995;24:330-5.
38. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial. Lancet 1999;353:259-66.
39. Proudman SM, Conaghan PG, Richardson C, et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000;43:1809-19.
40. Knijff-Dutmer E, Drossaers-Bakker W, Verhoeven A, et al. Rheumatoid factor measured by fluoroimmunoassay: a responsive measure of rheumatoid arthritis disease activity that is associated with joint damage. Ann Rheum Dis 2002;61:603-7.
41. Dixon JS, Pickup ME, Lowe JR, Hallett C, Lee MR, Wright V. Discriminatory indices of response of patients with rheumatoid arthritis treated with D-penicillamine. Ann Rheum Dis 1980;39:301-11.
42. Felix-Davies DD, Stewart AM, Wilkinson BR, Bateman JR, Delamere JP. A 12-month comparative trial of auranofin and P-penicillamine in rheumatoid arthritis. Am J Med 1983; Suppl 75:138-41.
43. Kim HA, Song YW. A comparison between bucillamine and D-penicillamine in the treatment of rheumatoid arthritis. Rheumatol Int 1997;17:5-9.
44. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995;38:1595-603.
45. Geborek P, Cmkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
46. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
47. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1999; 130:478-86.
48. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
49. Drynda S, Kuhne C, Kakow J. Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor β levels in rheumatoid arthritis. Ann Rheum Dis 2002;61:254-6.
50. Catrina AI, Lampa J, Ernestam S, et al. Anti-tumour necrosis factor-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology 2002;41:484-9.
51. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
52. Lipsky PE, van der Heijde DMFM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
53. Temekonidis TI, Georgiadis AN, Alamanos Y, Bougias DV, Voulgari PV, Drosos AA. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis 2002;61:822-5.
54. Scott DL, Dawes PT, Tunn E, et al. Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study. Br J Rheumatol 1989;28:128-33.
55. Wollheim FA, Hanson A, Laurell C-B. Chloroquine treatment in rheumatoid arthritis. Scand J Rheumatol 1978;7:171-6.
56. Rao URK, Naidu MUR, Kumar TR, et al. Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis - a double blind study. J Rheumatol 1995;22:1235-40.
57. van den Borne BEEM, Landewé RBM, Rietveld JH, et al. Chloroquine therapy in patients with recent-onset rheumatoid arthritis: the clinical response can be predicted by the low level of acute-phase reaction at baseline. Clin Rheumatol 1999;18:369-72.
58. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, the IL-1Ra Arthritis Study Group. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
59. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
60. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002;46:614-24.
61. Glennas A, Kvien TK, Andrup O, Clarke-Jenssen O, Karstensen B, Brodin U. Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. Br J Rheumatol 1997;36:870-7.
62. Blackburn WD Jr, Prupas HM, Silverfield JC, et al. Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine plus piroxicam, and piroxicam alone. Arthritis Rheum 1995;38:1447-56.
63. Kloppenburg M, Breedveld FC, Terwiel JPh, Mallee C, Dijkmans BAC. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 1994;37:629-36.
64. Stichtenoth DO, Fauler J, Zeidler H, Frolich JC. Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone. Ann Rheum Dis 1995;54:820-4.
65. Nishiya K, Hisakawa N, Tahara K, et al. Additive triple DMARD combination therapy of a low dose of sulfhydryl compounds, sulfasalazine and methotrexate in the treatment of rheumatoid arthritis: a clinical trial. Acta Med Okayama 1999;53:275-9.
66. Pascalis L, Aresu G, Pia G. Long-term efficacy and toxicity of cyclosporin A and fluocortolone and methotrexate in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 1999;17:679-88.
67. Rojkovich B, Hodinka L, Balint G, et al. Cyclosporin and sulfasalazine combination in the treatment of early rheumatoid arthritis. Scand J Rheumatol 1999;28:216-21.
68. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. Lancet 1999;353:1568-73.
69. Marchesoni A, Battafarano N, Arreghini M, et al. Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis. Arthritis Care Res 2002;47:59-62.
70. van der Heide A, Jacobs JWG, Schenk Y, Bijlsma JWJ. Endpoint measures in rheumatoid arthritis clinical trials: group summary and individual patient analysis. J Rheumatol 1994;21:2195-9.
71. ten Wolde S, Hermans J, Breedveld FC, Dijkmans BAC. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis 1997;56:235-9.
72. Sox HC, Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. Ann Intern Med 1986;104:515-23.
73. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997;24:1477-85.
74. Chaudhuri K, Torley H, Madhok R. Cyclosporin. Br J Rheumatol 1997;36:1016-21.
75. Paulus HE, Ramos B, Wong WK, et al. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. J Rheumatol 1999;26:2324-31.